Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury

References

• Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1–7. doi: 10.1016/S0140-6736(19)32563-2.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756–766. doi: 10.1016/S0140-6736(11)61454-2.
   PubMed Web of Science ®Google Scholar
• Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411–1423. doi: 10.1007/s00134-015-3934-7.
   PubMed Web of Science ®Google Scholar
• Ikizler TA, Parikh CR, Himmelfarb J, et al. A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death. Kidney Int. 2021;99(2):456–465. doi: 10.1016/j.kint.2020.06.032.
   PubMed Web of Science ®Google Scholar
• Odutayo A, Wong CX, Farkouh M, et al. AKI and long-term risk for cardiovascular events and mortality. J Am Soc Nephrol. 2017;28(1):377–387. doi: 10.1681/ASN.2016010105.
   PubMed Web of Science ®Google Scholar
• Nagata K, Horino T, Hatakeyama Y, et al. Effects of transient acute kidney injury, persistent acute kidney injury and acute kidney disease on the long-term renal prognosis after an initial acute kidney injury event. Nephrology (Carlton). 2021;26(4):312–318. doi: 10.1111/nep.13831.
   PubMed Web of Science ®Google Scholar
• Soto K, Campos P, Pinto I, et al. The risk of chronic kidney disease and mortality are increased after community-acquired acute kidney injury. Kidney Int. 2016;90(5):1090–1099. doi: 10.1016/j.kint.2016.07.018.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). J Am Med Assoc. 2016;315(8):801–810. doi: 10.1001/jama.2016.0287.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol. 2018;14(4):217–230. doi: 10.1038/nrneph.2017.184.
   PubMed Web of Science ®Google Scholar
• Peters E, Antonelli M, Wittebole X, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from the intensive care over nations audit. Crit Care. 2018;22(1):188. doi: 10.1186/s13054-018-2112-z.
   PubMedGoogle Scholar
• Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2(3):431–439. doi: 10.2215/CJN.03681106.
   PubMed Web of Science ®Google Scholar
• Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3–4):157–172. doi: 10.1155/2009/504294.
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Ajeti V, Ljunggren L. Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels. Biomark Insights. 2011;6:119–125. doi: 10.4137/BMI.S8326.
   PubMedGoogle Scholar
• Rabna P, Andersen A, Wejse C, et al. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study. Inflammation. 2010;33(6):374–380. doi: 10.1007/s10753-010-9195-2.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Koh KH, Grams ME, et al. A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease. Nat Med. 2017;23(8):945–953. doi: 10.1038/nm.4362.
   PubMed Web of Science ®Google Scholar
• Wei C, Li J, Adair BD, et al. uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. J Clin Invest. 2019;129(5):1946–1959. doi: 10.1172/JCI124793.
   PubMed Web of Science ®Google Scholar
• Wei C, Möller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14(1):55–63. doi: 10.1038/nm1696.
   PubMed Web of Science ®Google Scholar
• Jhee JH, Nam BY, Lee CJ, et al. Soluble urokinase-type plasminogen activator receptor, changes of 24-Hour blood pressure, and progression of chronic kidney disease. J Am Heart Assoc. 2021;10(1):e017225. doi: 10.1161/JAHA.120.017225.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382(5):416–426. doi: 10.1056/NEJMoa1911481.
   PubMed Web of Science ®Google Scholar
• Huang Q, Xiong H, Yan P, et al. The diagnostic and prognostic value of suPAR in patients with sepsis: a systematic review and Meta-Analysis. Shock. 2020;53(4):416–425. doi: 10.1097/SHK.0000000000001434.
   PubMed Web of Science ®Google Scholar
• Nasr El-Din A, Abdel-Gawad AR, Abdelgalil W, et al. Evaluation of sTREM1 and suPAR biomarkers as diagnostic and prognostic predictors in sepsis patients. Infect Drug Resist. 2021;14:3495–3507. doi: 10.2147/IDR.S314237.
   PubMed Web of Science ®Google Scholar
• Efat A, Shoeib SA, Arafa AF, et al. Thrombo-inflammatory biomarkers to predict sepsis outcome. Int J Immunopathol Pharmacol. 2021;35:20587384211048561. doi: 10.1177/20587384211048561.
   Web of Science ®Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–184. doi: 10.1159/000339789.
   PubMedGoogle Scholar
• Mossanen JC, Pracht J, Jansen TU, et al. Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery. Int J Mol Sci. 2017;18(8):1662. doi: 10.3390/ijms18081662.
   PubMed Web of Science ®Google Scholar
• Walls AB, Bengaard AK, Iversen E, et al. Utility of suPAR and NGAL for AKI risk stratification and early optimization of renal risk medications among older patients in the emergency department. Pharmaceuticals (Basel). 2021;14(9):843. doi: 10.3390/ph14090843.
   PubMedGoogle Scholar
• Qin Y, Qiao Y, Wang D, et al. The predictive value of soluble urokinase-type plasminogen activator receptor in Contrast-Induced acute kidney injury in patients undergoing percutaneous coronary intervention. Int J Gen Med. 2021;14:6497–6504. doi: 10.2147/IJGM.S339075.
   PubMed Web of Science ®Google Scholar
• Chew-Harris J, Appleby S, Richards AM, et al. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals. Clin Biochem. 2019;69:36–44. doi: 10.1016/j.clinbiochem.2019.05.010.
   PubMed Web of Science ®Google Scholar
• Desmedt S, Desmedt V, Delanghe JR, et al. The intriguing role of soluble urokinase receptor in inflammatory diseases. Crit Rev Clin Lab Sci. 2017;54(2):117–133. doi: 10.1080/10408363.2016.1269310.
   PubMed Web of Science ®Google Scholar
• Peerapornratana S, Manrique-Caballero CL, Gómez H, et al. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019;96(5):1083–1099. doi: 10.1016/j.kint.2019.05.026.
   PubMed Web of Science ®Google Scholar
• Tsai PK, Tsao SM, Yang WE, et al. Plasma soluble urokinase-type plasminogen activator receptor level as a predictor of the severity of Community-Acquired pneumonia. Int J Environ Res Public Health. 2019;16(6):1035. doi: 10.3390/ijerph16061035.
   PubMed Web of Science ®Google Scholar